Difference in Cost-Effectiveness of Trastuzumab Deruxtecan in First-Line Versus Later-Line Settings for HER2-Low Metastatic Breast Cancer
Annals of Pharmacotherapy · 27.05.2026
DOI: 10.1177/10600280261447399 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 27.05.2026. Verfasst von Munenobu Kashiwa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Comprehensive Unit for Health Economic Evidence Review and Decision Support (CHEERS), Research Organization of Science and Technology, Ritsumeikan Un…. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
Trastuzumab deruxtecan (T-DXd) is approved as first-line therapy for HER2-low metastatic breast cancer after endocrine therapy failure and as later-line therapy, but economic evidence comparing these two settings to inform sequencing decisions is lacking.
Objective
To compare the cost-effectiveness of T-DXd between first-line and later-line settings for HER2-low metastatic breast cancer from a Japanese healthcare payer perspective.
Methods
A partitioned survival model was developed using data from the DESTINY-Breast06 and DESTINY-Breast04 trials. The analysis adopted a Japanese healthcare payer perspective with a 30-year time horizon and 2% annual discounting for both costs and outcomes. Incremental cost-effectiveness ratios (ICERs) were compared against a willingness-to-pay threshold of 15 million JPY per quality-adjusted life-year (QALY). Deterministic, probabilistic, and scenario sensitivity analyses were conducted.
Results
T-DXd yielded an ICER of 37.36 million JPY/QALY in the first-line setting and 63.29 million JPY/QALY in the later-line setting compared with physician’s choice chemotherapy. Sensitivity analyses confirmed the robustness of these estimates, with first-line T-DXd consistently more favourable across scenarios. Conclusion and Relevance: T-DXd exceeded the willingness-to-pay threshold in both settings at current pricing, indicating it was not cost-effective. Although the first-line ICER was approximately 40% lower than the later-line ICER, achieving cost-effectiveness in the first-line setting requires a larger proportional price reduction because the comparator chemotherapy in that setting is less expensive. This first Japanese cost-effectiveness analysis directly comparing the two settings should inform pricing negotiations and highlight the need for predictive biomarkers of the T-DXd response.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Comprehensive Unit for Health Economic Evidence Review and Decision Support (CHEERS), Research Organization of Science and Technology, Ritsumeikan University, Kusatsu, Japan.
- Laboratory of Clinical Pharmacy and Healthcare Science, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Japan.
ORCID-Profile: Munenobu Kashiwa
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Kashiwa, M., & Fujimori, M. (2026). Difference in Cost-Effectiveness of Trastuzumab Deruxtecan in First-Line Versus Later-Line Settings for HER2-Low Metastatic Breast Cancer. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280261447399
Vancouver
Kashiwa M, Fujimori M. Difference in Cost-Effectiveness of Trastuzumab Deruxtecan in First-Line Versus Later-Line Settings for HER2-Low Metastatic Breast Cancer. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280261447399
BibTeX
@article{Kashiwa2026,
author = {Kashiwa, Munenobu and Fujimori, Maya},
title = {Difference in Cost-Effectiveness of Trastuzumab Deruxtecan in First-Line Versus Later-Line Settings for HER2-Low Metastatic Breast Cancer},
journal = {Annals of Pharmacotherapy},
year = {2026},
doi = {10.1177/10600280261447399}
}
EUVIMED